Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2020 in Stargardt-type Macular Dystrophies
NCT07734064Phase 1Recruiting
- Sponsor
- Astellas Institute for Regenerative Medicine
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP2020 in Stargardt disease (STGD) and macular dystrophy (6 arms), sponsored by Astellas Institute for Regenerative Medicine. Primary endpoints: Treatment-Emergent Adverse Events up to 52 weeks, Serious Adverse Events up to 52 weeks and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
ASP2020
03
Conditions
Stargardt disease (STGD)macular dystrophy
Beyond the preview
Go deeper on NCT07734064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734064.